CSS
AVIR icon

Cubist Systematic Strategies’s Atea Pharmaceuticals AVIR Stock Holding History

Cubist Systematic Strategies’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$255K Buy
+87,774
New +$300K ﹤0.01% 2577
2024
Q3 		– Sell
-34,045
Closed -$113K – 2978
2024
Q2 		$113K Sell
34,045
-60,080
-64% -$224K ﹤0.01% 2608
2024
Q1 		$380K Sell
94,125
-84,228
-47% -$330K ﹤0.01% 2770
2023
Q4 		$544K Buy
178,353
+39,280
+28% +$119K ﹤0.01% 2480
2023
Q3 		$417K Buy
139,073
+98,081
+239% +$334K ﹤0.01% 2415
2023
Q2 		$153K Sell
40,992
-34,570
-46% -$129K ﹤0.01% 2900
2023
Q1 		$253K Buy
75,562
+34,438
+84% +$140K ﹤0.01% 3084
2022
Q4 		$198K Buy
+41,124
New +$208K ﹤0.01% 3587
2022
Q3 		– Sell
-26,656
Closed -$189K – 4415
2022
Q2 		$189K Sell
26,656
-97,884
-79% -$668K ﹤0.01% 3735
2022
Q1 		$899K Sell
124,540
-301,280
-71% -$2.05M 0.01% 2114
2021
Q4 		$3.81M Buy
425,820
+417,795
+5,206% +$6.51M 0.04% 843
2021
Q3 		$281K Sell
8,025
-37,432
-82% -$1.04M ﹤0.01% 2395
2021
Q2 		$976K Buy
45,457
+40,557
+828% +$1.22M 0.01% 1590
2021
Q1 		$303K Buy
+4,900
New +$331K ﹤0.01% 2245

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cubist Systematic Strategies's AVIR Position: Q3 2025 in Review

Cubist Systematic Strategies opened a new position in Atea Pharmaceuticals (AVIR) in Q3 2025: 87,774 shares worth $255K. The stake represents ﹤0.01% of the portfolio and ranks #2577 among its holdings. This is a return to the name: Cubist Systematic Strategies previously reported a position in AVIR as recently as Q2 2024.

Cubist Systematic Strategies first reported a position in AVIR in Q1 2021 and has held it in 14 quarters since. The position peaked at $3.81M in Q4 2021. 115 funds tracked by Wall St. Rank hold AVIR as of Q3 2025.

  • Cubist Systematic Strategies held 87,774 shares of Atea Pharmaceuticals worth $255K as of Q3 2025.
  • Atea Pharmaceuticals was a new Cubist Systematic Strategies position in Q3 2025.
  • Atea Pharmaceuticals made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2577 holding.
  • Cubist Systematic Strategies first reported a position in Atea Pharmaceuticals in Q1 2021 and has held it in 14 quarters since.
  • Cubist Systematic Strategies's Atea Pharmaceuticals position peaked at $3.81M in Q4 2021.
  • 115 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.